Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HER2+
•
Breast Cancer, Metastatic
How do you approach treatment in a young de novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Related Questions
What are your top takeaways in Breast Cancer from ESMO 2024?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
What are your top takeaways in Breast Cancer from ASTRO 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you consider treatment with alpelisib plus fulvestrant or with Enhertu?
